Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn's Disease

Full text
Author(s):
de Paula-Silva, Marina [1, 2] ; Oliveira da Rocha, Gustavo Henrique [1] ; Broering, Milena Fronza [1] ; Queiroz, Maria Luiza [3] ; Sandri, Silvana [1] ; Loiola, Rodrigo Azevedo [1] ; Oliani, Sonia Maria [4] ; Vieira, Andrea [3] ; Perretti, Mauro [2] ; Poliselli Farsky, Sandra Helena [1]
Total Authors: 10
Affiliation:
[1] Univ Sao Paulo, Dept Clin & Toxicol Anal, Sao Paulo - Brazil
[2] Queen Mary Univ London QMUL, Ctr Biochem Pharmacol, Barts & London Sch Med, William Harvey Res Inst, London - England
[3] Irmandade Santa Casa Misericordia Sao Paulo, Gastroenterol Serv, Sao Paulo - Brazil
[4] Sao Paulo State Univ UNESP, Dept Biol, Sao Jose Rio do Preto, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: FRONTIERS IN IMMUNOLOGY; v. 12, SEP 17 2021.
Web of Science Citations: 0
Abstract

Non-responsiveness to anti-TNF-alpha therapies presents relevant rates in inflammatory bowel disease patients, presenting the need to find biomarkers involved in therapeutic efficacy. Herein, we demonstrate that higher levels of colonic formyl peptide receptor 1 and annexin A1 correlate with histological recovery in Crohn's disease patients under remission. Using the dextran sulfate sodium colitis model in mice, we suggest that infliximab induces annexin A1 expression and secretion in activated intestinal leukocytes. Conversely, this mechanism might stimulate epithelial formyl peptide receptors, inducing wound healing and consequent histological remission. Our data indicate that assessing intestinal expressions of formyl peptide receptors and annexin A1 might provide precious information on the disease activity and responsiveness to infliximab in inflammatory bowel disease patients.</p> (AU)

FAPESP's process: 14/07328-4 - Identification of endogenous pathways for the control of inflammation
Grantee:Sandra Helena Poliselli Farsky
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 19/02806-9 - Involvement of formyl-peptide receptor pathways and ligands in the efficacy of infliximab therapy
Grantee:Marina de Paula Silva
Support Opportunities: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 16/19682-2 - Annexin A1 pathways triggered in the inflammatory bowel disease treated with infliximab
Grantee:Marina de Paula Silva
Support Opportunities: Scholarships in Brazil - Doctorate